GFC Life Science Co., Ltd (KOSDAQ:388610)
South Korea
· Delayed Price · Currency is KRW 18,100
-620 (-3.31%)
At close: Aug 13, 2025, 3:30 PM KST
GFC Life Science Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | 2016 |
| Operating Revenue | 13,737 | 13,324 | 11,908 | 8,679 | 7,161 | Upgrade
|
| Other Revenue | -0 | -0 | -0 | - | - | Upgrade
|
| Revenue | 13,737 | 13,324 | 11,908 | 8,679 | 7,161 | Upgrade
|
| Revenue Growth (YoY) | 3.09% | 11.89% | 37.21% | 21.20% | 2.20% | Upgrade
|
| Cost of Revenue | 7,283 | 7,397 | 8,024 | 5,727 | 4,556 | Upgrade
|
| Gross Profit | 6,453 | 5,927 | 3,884 | 2,951 | 2,605 | Upgrade
|
| Selling, General & Admin | 3,709 | 4,117 | 3,458 | 2,158 | 1,856 | Upgrade
|
| Research & Development | 841 | 967.78 | 694.73 | 1,200 | 1,648 | Upgrade
|
| Other Operating Expenses | 40.17 | 32.89 | 29.46 | 55.66 | 27.38 | Upgrade
|
| Operating Expenses | 5,075 | 5,935 | 4,642 | 4,580 | 3,821 | Upgrade
|
| Operating Income | 1,379 | -7.37 | -757.9 | -1,628 | -1,216 | Upgrade
|
| Interest Expense | -218.09 | -205.48 | -219.46 | -134.14 | -80.36 | Upgrade
|
| Interest & Investment Income | 6.18 | 94.1 | 148.02 | 10.57 | 9.52 | Upgrade
|
| Earnings From Equity Investments | - | -323.54 | 217.23 | 1,126 | 394.96 | Upgrade
|
| Currency Exchange Gain (Loss) | 5.34 | -4.83 | 2.57 | 6.17 | -6.37 | Upgrade
|
| Other Non Operating Income (Expenses) | 48.91 | -1,907 | 154.12 | 1.05 | -40.23 | Upgrade
|
| EBT Excluding Unusual Items | 1,221 | -2,355 | -455.42 | -618.92 | -938.52 | Upgrade
|
| Gain (Loss) on Sale of Investments | 56.46 | 43.9 | 88.57 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 172.58 | - | 835.46 | 118.93 | 3.17 | Upgrade
|
| Asset Writedown | -42.72 | -96.86 | - | - | - | Upgrade
|
| Other Unusual Items | 250 | - | - | - | - | Upgrade
|
| Pretax Income | 1,657 | -2,407 | 468.61 | -499.99 | -935.35 | Upgrade
|
| Income Tax Expense | 15.99 | - | 19.91 | - | - | Upgrade
|
| Earnings From Continuing Operations | 1,641 | -2,407 | 448.7 | -499.99 | -935.35 | Upgrade
|
| Earnings From Discontinued Operations | -24.41 | -455.09 | - | - | - | Upgrade
|
| Net Income | 1,617 | -2,863 | 448.7 | -499.99 | -935.35 | Upgrade
|
| Net Income to Common | 1,617 | -2,863 | 448.7 | -499.99 | -935.35 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 1 | Upgrade
|
| Shares Change (YoY) | 0.01% | 0.02% | 100.00% | -50.03% | 0.06% | Upgrade
|
| EPS (Basic) | 1560.00 | -2762.00 | 433.00 | -965.00 | -902.00 | Upgrade
|
| EPS (Diluted) | 1560.00 | -2762.00 | 433.00 | -965.00 | -902.00 | Upgrade
|
| Free Cash Flow | 357.14 | -1,934 | -4,007 | -7,347 | -1,931 | Upgrade
|
| Free Cash Flow Per Share | 344.54 | -1865.79 | -3867.17 | -14179.32 | -1862.49 | Upgrade
|
| Gross Margin | 46.98% | 44.49% | 32.62% | 34.01% | 36.38% | Upgrade
|
| Operating Margin | 10.04% | -0.06% | -6.36% | -18.76% | -16.98% | Upgrade
|
| Profit Margin | 11.77% | -21.48% | 3.77% | -5.76% | -13.06% | Upgrade
|
| Free Cash Flow Margin | 2.60% | -14.51% | -33.65% | -84.65% | -26.97% | Upgrade
|
| EBITDA | 2,282 | 755.2 | 36.25 | -1,167 | -948.29 | Upgrade
|
| EBITDA Margin | 16.61% | 5.67% | 0.30% | -13.44% | -13.24% | Upgrade
|
| D&A For EBITDA | 903.41 | 762.56 | 794.15 | 461.4 | 267.76 | Upgrade
|
| EBIT | 1,379 | -7.37 | -757.9 | -1,628 | -1,216 | Upgrade
|
| EBIT Margin | 10.04% | -0.06% | -6.36% | -18.76% | -16.98% | Upgrade
|
| Effective Tax Rate | 0.97% | - | 4.25% | - | - | Upgrade
|
| Advertising Expenses | 342.12 | 277.48 | 387.96 | 249.57 | 16.54 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.